Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,395 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumor Clear all
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 3 Interventional

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

NCT06395441
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
American Ginseng, Placebo Administration, Questionnaire Administration
Dietary Supplement · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Albert Lea, Minnesota • Bemidji, Minnesota • Brainerd, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional

An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy

NCT04054154
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Shear Wave Elastography, Tumor Interstitial Fluid Pressure Measurement
Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

NCT06308822
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Erdafitinib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NCT05071183
View directory record Official record
Conditions
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
TPX-0005, Trametinib
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
California City, California • Denver, Colorado • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

NCT00640796
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma, Myelodysplastic Syndrome
Interventions
Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS
Procedure · Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

NCT00500903
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional

Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device

NCT05096286
View directory record Official record
Conditions
Intracranial Metastatic Disease From Any Solid Malignancy
Interventions
Ethos Therapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

NCT06521554
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
NVL-330
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Irvine, California • Sacramento, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

NCT02722954
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
Demcizumab, Pembrolizumab
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Denver, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

NCT07356453
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
FORX-428
Drug
Lead sponsor
FoRx Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

NCT00057720
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
234
States / cities
Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Jul 22, 2026, 10:41 AM EDT
Completed No phase listed Observational

Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)

NCT02071056
View directory record Official record
Conditions
Leptomeningeal Metastasis
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

NCT02679131
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions
Belinostat
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

NCT00422682
View directory record Official record
Conditions
Tumors
Interventions
bsi-201 + topotecan, bsi-201 + temozolomide, bsi-201 + gemcitabine, bsi-201 + carboplatin/paclitaxel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
New Haven, Connecticut • Detroit, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Tabectedin to Treat Children and Adolescents With Cancer

NCT01453283
View directory record Official record
Conditions
Solid Tumors
Interventions
Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-1761981 in Participants With Solid Tumors

NCT07525141
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-1761981, Cetrelimab
Drug
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

NCT00381654
View directory record Official record
Conditions
Tumor
Interventions
AV-412
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01923337
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, alisertib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

NCT01628640
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

NCT00019760
View directory record Official record
Conditions
Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
Interventions
floxuridine, leucovorin calcium, melphalan
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jul 22, 2026, 10:41 AM EDT